Morrisville, N.C.-based Tear- Science Inc., which makes treat- ments for meibomian gland dysfunction (MGD), has appointed a new president and CEO. Joseph Boorady, O.D., joined TearScience from Carl Zeiss Meditec Inc. where he was senior vice president of U.S. sales, marketing, and customer service for all medical products.
Boorady replaces current CEO and co-founder Tim Willis.
ing 36 clinics throughout New York City.
at the ophthalmic technology giant.
The TearScience System, which includes LipiView II, the Korb Meibomian Gland Evaluator, and LipiFlow, is designed to identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and vision clarity, causes ocular discomfort and is the root cause of most dry eye.
Bovie Medical Corporation has hired an R&D director to enhance its product development efforts.
The company recently appointed Shawn D. Roman to the role to “further develop and execute”the company’s product portfolio from research through product launch.
Prior to joining Bovie, Roman worked as general manager, co-innovation and, earlier, as an engineering manager at CoorsTek Medical (formerly Innovative Medical Device Solutions). Before that, he spent 14 years with Biomet Microfixation Inc., a business division of Biomet Inc., in several roles, including vice president of Research & Development, director of Development Engineering and senior development engineer.
ties,” Bovie CEO Robert L. Gershon said.
Based in Clearwater, Fla., Bovie Medical Corporation manufactures and supplies medical devices. Its surgical product uses a gas ionization process that produces a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical also manufactures a range of electrosurgical products and technologies, marketed through both private labels and the company’s own brands (Bovie, Aaron, IDS and ICON) to distributors worldwide.